Difamilast Ointment Eases Eczema Severity and Itch
Pooled phase 2 and 3 data show difamilast 1% improved atopic dermatitis severity and itch within one week in adults and children.
Updated on Nov. 2, 2026 in Asthma
Pooled phase 2 and 3 trial data for difamilast 1% ointment were presented at the 2026 Fall Clinical Dermatology Conference in Las Vegas, Nevada. The results show improvements in disease severity and itch within one week in adults and children with mild to moderate atopic dermatitis.
Why it matters
Atopic dermatitis is a common chronic skin condition, and the FDA approved difamilast in February 2026 for patients aged 2 years and older. The pooled data add evidence on how quickly the treatment acts across age groups in the trial program.
Phase 3 trials showed IGA success at week 4 of 38.46% for difamilast 1% in adults and adolescents versus 12.64% for vehicle, and 47.1% in children versus 18.1% for vehicle. The data do not extend beyond week 4 in the reported trials.
The details
Investigators randomized 121 individuals aged 10 to 70 to difamilast 1%, difamilast 0.3%, or vehicle for 8 weeks in a phase 2 trial, and 365 subjects aged 15 to 70 to difamilast 1% or vehicle for 4 weeks in a first phase 3 trial. A second phase 3 trial enrolled 251 children aged 2 to 14, and no clinically meaningful gastrointestinal safety signals, including diarrhea, were observed across the program.
Timeline
February 2026: FDA approved difamilast for patients aged 2 years and older with mild to moderate atopic dermatitis.
Week 1: Early improvement in disease severity and itch was observed in the trials.
Week 4: Primary efficacy endpoints were measured in the phase 3 trials.
Fall 2026: Pooled program data were presented at the Clinical Dermatology Conference in Las Vegas.
Health Landscape
The February 2026 FDA approval of difamilast for patients aged 2 years and older with mild to moderate atopic dermatitis places this topical treatment among options for a broad age range. The pooled phase 2 and 3 data add comparative efficacy details that bear on how it fits alongside existing topical therapies.
Patients and caregivers with mild to moderate atopic dermatitis may discuss difamilast with a clinician now that it is FDA-approved for ages 2 and older. The trial data show early improvement in itch and severity within one week, though the source does not address long-term use or cost.
The takeaway
Early improvement within one week was reported across age groups in the difamilast trials. Anyone considering treatment should review results and options with a healthcare provider.
Further reading
Explore more on Asthma and related respiratory and allergic conditions.
